Guggenheim lowered the firm’s price target on AstraZeneca to 13,100 GBp from 13,400 GBp and keeps a Buy rating on the shares. The firm updated its model ahead of Q2 results to reflect prescription trends and recent commentary from management.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Tagrisso approved in EU as first-line treatment for lung cancer
- AstraZeneca price target raised to 11,700 GBp from 11,300 GBp at Jefferies
- AstraZeneca’s MAA for sipavibart accepted by EMA for COVID-19 prevention
- AstraZeneca’s Imfinzi, Lynparza recommended for approval in EU by CHMP
- AstraZeneca says Tagrisso with addition of chemo approved in China for NSCLC